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Abstract
Background: The development of cancer has been associated with epigenetic alterations such as aberrant histone deacetylase
(HDAC) activity. It was recently reported that valproic acid is an effective inhibitor of histone deacetylases and as such induces
tumor cell differentiation, apoptosis, or growth arrest.
Methods: Twelve newly diagnosed patients with cervical cancer were treated with magnesium valproate after a baseline tumor
biopsy and blood sampling at the following dose levels (four patients each): 20 mg/kg; 30 mg/kg, or 40 mg/kg for 5 days via oral
route. At day 6, tumor and blood sampling were repeated and the study protocol ended. Tumor acetylation of H3 and H4
histones and HDAC activity were evaluated by Western blot and colorimetric HDAC assay respectively. Blood levels of valproic
acid were determined at day 6 once the steady-state was reached. Toxicity of treatment was evaluated at the end of study
period.
Results: All patients completed the study medication. Mean daily dose for all patients was 1,890 mg. Corresponding means for
the doses 20-, 30-, and 40-mg/kg were 1245, 2000, and 2425 mg, respectively. Depressed level of consciousness grade 2 was
registered in nine patients. Ten patients were evaluated for H3 and H4 acetylation and HDAC activity. After treatment, we
observed hyperacetylation of H3 and H4 in the tumors of nine and seven patients, respectively, whereas six patients
demonstrated hyperacetylation of both histones. Serum levels of valproic acid ranged from 73.6–170.49 µg/mL. Tumor
deacetylase activity decreased in eight patients (80%), whereas two had either no change or a mild increase. There was a
statistically significant difference between pre and post-treatment values of HDAC activity (mean, 0.36 vs. 0.21, two-tailed t test
p < 0.0264). There was no correlation between H3 and H4 tumor hyperacetylation with serum levels of valproic acid.
Conclusion: Magnesium valproate at a dose between 20 and 40 mg/kg inhibits deacetylase activity and hyperacetylates histones
in tumor tissues.
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Background
The development of cancer has been associated with epi-
genetic alterations such as deregulation of DNA methyla-
tion and aberrant histone deacetylase (HDAC) activity
[1]. These epigenetic phenomena co-participate in regula-
tion of gene transcription: for instance, histone deacety-
lases which deacetylate histone core tails are recruited by
DNA methyltransferases and methyl-binding proteins,
which in turn lead to tighter chromatin packaging, reduc-
ing access of transcriptional factors to DNA [2,3].
HDACs are seen as a potential target for cancer treatment.
HDAC inhibition has been reported to induce tumor cell
differentiation, apoptosis, or growth arrest, depending on
the experimental system [4-7]. Previous studies have
shown that histone acetylation can increase the efficiency
of several anticancer drugs targeting the DNA [8-11]; stud-
ies also shown that HDAC activity inhibitors enhance in
vitro sensitivity of tumor cells to radiation [12-14]. How-
ever, a significant impediment in targeting HDAC has
been lack of a clinically applicable HDAC inhibitor.
Valproic acid, an 8-carbon, branched-chained fatty acid, is
a well-known and effective antiepileptic drug [15]. Its
pharmacologic effects involve a variety of mechanisms
including increased gamma-amino butyric acid (GABA)-
ergic transmission, reduced release and/or effects of exci-
tatory amino acids, blockade of voltage-gated sodium
channels, and modulation of dopaminergic and serot-
oninergic transmission [16]. Because of its effectiveness,
good tolerability, and oral bioavailability, valproic acid is
widely used as a chronic anti-convulsant therapy.
It was recently reported that valproic acid is an effective
inhibitor of histone deacetylases at concentrations well
within the therapeutic range used for epilepsy. As such,
valproic acid relieves repression of transcription factors
that recruit histone deacetylases and activates transcrip-
tion from diverse promoters. Valproic acid causes hyper-
acetylation of the N-terminal tails of histones H3 and H4
in vitro and in vivo. It inhibits HDAC activity, most proba-
bly by binding to the catalytic center and thereby blocking
substrate access [17,18].
In contrast to other HDAC inhibitors, valproic acid has a
good tolerability and safety profile as demonstrated by 35
years of use as a chronic therapy for epileptic disorders. It
has a serum half-life of 9–18 h and is administered orally
[15,16]; however, the dose needed for observing its
HDAC inhibitory activity in tumors of cancer patients is
yet unknown. On these basis, we performed a phase I
study to find the biologically "adequate" dose of magne-
sium valproate that would induce achieve histone acetyla-
tion and inhibition of HDAC in tumors of patients with
cervical cancer.
Results
Study group
A total of 12 patients were studied. All of were chemother-
apy- or radiation-naive and had a macroscopic tumor
accessible for punch biopsy. Patient mean age was 63.3
years (44–72 years), while the majority of cases were squa-
mous histology and were staged as FIGO stages IIB and
IIIB. Status performance was 0–1 in most patients (Table
1).
Treatment compliance and side effects
All patients completed the study medication. Weight of
patients varied from 45–82 kg and mean daily dose for all
patients was 1,890 mg. According to dose level, mean
daily dose for the 20-mg/kg dose level was 1245 mg
(range, 1000–1400 mg), while it was 2000 mg (1800–
2100) for the 30 mg/kg- and 2425 mg (1800–3300) for
the 40-mg/kg dose level. Treatment in general was well-
tolerated. Table 2 shows toxicity recorded according to the
Common Toxicity Criteria (CTC). As expected, the most
common side effect was depressed level of consciousness
that in no case was grade 3 or 4. Thus, three of four
patients at the 20-mg and 30-mg dose levels presented
this event graded as 2, whereas one and three patients
were graded 1 and 2, respectively, at the 40-mg dose; by
definition, these side effects did not interfere with the
daily living activities of patients. The next effect in fre-
quency was fatigue; also grade 2 in three patients at the
20-mg dose level and in one patient at the 30-mg dose.
Other side effects such as nausea, diarrhea, anorexia, and
dizziness/lightheadedness were uncommon and mild.
There were no changes in the values of non-hematological
or hepatic parameters except by lymphopenia grade 1 in a
patient receiving the lowest dose level. All toxicities disap-
peared within the ensuing week.
Table 1: Clinical characteristics of patients
Number 12
Mean age (years) 63.3 (72–44)
Histology
Squamous 8 (66%)
Adenocarcinoma 4 (33%)
FIGO stage*
IIB 3 (25%)
IIIB 8 (66%)
IVB 1 (08%)
Performance status**
0 1 (17%)
1 9 (75%)
2 2 (08%)
*FIGO = International Federation of Gynecology and Obstetrics; ** 
World Health Organization (WHO) criteria.Molecular Cancer 2005, 4:22 http://www.molecular-cancer.com/content/4/1/22
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Histone acetylation of tumors
Pre- and post-treatment tumor samples of all 12 patients
were collected; however, the effect of valproate treatment
on histone acetylation by Western blot of H3 and H4
could not be assessed in two patients because amount and
quality of tumor samples of either pre- or post-treatment
biopsies were not adequate. These two patients (numbers
2 and 4) belonged to the 20-mg/kg dose level. Figures 1,
2, and 3 are Western blots of the patients analyzed. The
first observation is the ample heterogeneity in degree of
baseline acetylation in both H3 and H4 histones. Pre-
treatment band was hardly seen for acetylated H3 in
patients 1 and 11, whereas it was very strong in patient 6;
likewise, acetylated H4 was very weak in patients 3, 5, and
11. In assessment of valproate treatment effect, there was
variable increase in band intensity, indicative of hyper-
acetylation of H3 in all patients except in patient 6. With
regard to acetylation of H4, seven patients (1, 3, 5, 6, 7,
11, and 12) had clear hyperacetylation, whereas in the
remaining individuals (patients 8, 9, and 10) the effect
was minor or non-existent. As can be seen, both H3 and
H4 hyperacetylation was observed in patients 1, 3, 5, 7, 11
and 12.
Serum Levels of valproic acid
Blood serum levels of valproic acid after the 5-day treat-
ment period are shown in Figures 1, 2, and 3, respectively.
Samples were taken and analyzed in all cases. Levels
ranged from 73.6–170.49 µg/mL. There was lack of corre-
lation between serum levels with dose level. Thus, values
for patients were as follows: at the 20-mg/kg dose level
80.79, 98.92, 109.12, and 87.43, for a mean of 94.06 µg/
mL; for the 30-mg/kg level 146.56, 81.20, 170.49, and
95.60, for a mean of 123.46 µg/mL, and finally for the
highest dose level of 40 mg/kg, corresponding values were
88.47, 94.18, 107.47, and 73.61, with a mean of 90.93
µg/mL.
Histone deacetylase assay in tumors
To investigate whether a decrease in histone acetylase
activity could be achieved by valproate treatment in the
tumors, enzyme activity was evaluated in tumor biopsies
extracts by colorimetric commercial HDAC activity assay
in 10 patients; Results are also shown in Figures 1, 2, and
3. Using the same scale for positive and negative control,
we found that 8 of 12 (75%) patients had a decrease in
deacetylase activity equal to or greater that observed in
HeLa cell extracts treated or not with trichostatinA,
whereas patients 3 and 8 (25%) had either no change or a
mild increase in deacetylase activity. Pooling the absolute
values of optical densities (ODs) for pre- and post-treat-
ment samples, there was a statistically significant differ-
ence between values (mean 0.36 vs. 0.21, respectively, for
a 0.142 mean difference 95% confidence interval (CI
95%) 0.020–0.264), two-tailed t test (p < 0.0264). Our
small sample size did not allow for establishing a correla-
tion with H3 and H4 histone acetylation. Remarkably,
cases 3 and 8-who showed no HDAC inhibition had
tumor hyperacetylation. The patient 3 in both histones
whereas the patient 8 only in H3.
H3 and H4 Acetylation in PBMN cells
Due to limitations in amount of blood samples, histone
acetylation by Western blot could be assayed only in four
patients (1, 2, 5, and 8). Figure 4 shows that all four
showed hyperacetylation after treatment in comparison
with pre-treatment samples for both H3 and H4 histones.
Discussion
The balance between histone deacetylases and histone
acetyl transferase activities is a major player in regulation
of gene transcription [19]. HDAC inhibition induces accu-
mulation of hyperacetylated nucleosome core histones in
the majority of chromatin regions but affects expression
of only a small subset of genes, leading to transcriptional
Table 2: Toxicity to valproate expressed by number of patients suffering the event
Toxicity 4 patients at each dose level (mg/kg)
20 30 40
Depressed level of consciousness* 3 (g2) 3(g2) 1(g1), 3(g2)
Nausea - 1 (g1), 1(g2) 1 (g2)
Diarrhea - - -
Fatigue 3 (g2) 1(g2) -
Anorexia - 1(g2) -
Dizziness/lightheadedness - 1(g2) -
*Grade 2 toxicity. All others were grade 1.
Depressed level of consciousness (g1: somnolence or sedation not interfering with function; g2: somnolence or sedation interfering with function 
but not interfering with activities of daily living; g3: obtundation or stupor, difficulty to arouse, interfering with daily living; g4) coma.Molecular Cancer 2005, 4:22 http://www.molecular-cancer.com/content/4/1/22
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activation of some but repression of an equal or larger
number of other genes [20,21]. This led to testing HDAC
inhibitors as anticancer agents in a variety of tumor mod-
els and clinical studies. To date, a number of structurally
distinct classes of compounds have been identified as
HDAC inhibitors including hydroxamates, cyclic
Western blots for anti-acetylated H3 and H4 histones pre-  and post-treatment in patients receiving a dose of 20 mg/kg Figure 1
Western blots for anti-acetylated H3 and H4 histones pre- 
and post-treatment in patients receiving a dose of 20 mg/kg. 
Patients 2 and 4 are missed due to insufficient sample. Posi-
tive and negative controls are HeLa cells treated or not with 
trichostatinA. Loading control are gels stained with coomas-
sie blue. Graphs in the inferior panel are HDAC activity 
expressed as optical densities (ODs), in the same scale as 
positive and negative controls that are also HeLa cells 
extracts with and without trichostatinA treatment. At the 
bottom are values of valproic acid in serum.
Western blots for anti-acetylated H3 and H4 histones pre-  and post-treatment in patients receiving a dose of 30 mg/kg Figure 2
Western blots for anti-acetylated H3 and H4 histones pre- 
and post-treatment in patients receiving a dose of 30 mg/kg. 
Positive and negative controls are HeLa cells treated or not 
with trichostatin A. Loading control are gels stained with 
coomassie blue. Graphs in the inferior panel are HDAC 
activity expressed as ODs, in the same scale as positive and 
negative controls that are also HeLa cells extracts with and 
without trichostatinA treatment. At the bottom are values of 
valproic acid in serum.
Western blots for anti-acetylated H3 and H4 histones pre-  and post-treatment in patients receiving a dose of 40 mg/kg Figure 3
Western blots for anti-acetylated H3 and H4 histones pre- 
and post-treatment in patients receiving a dose of 40 mg/kg. 
Positive and negative controls are HeLa cells treated or not 
with trichostatin A. Loading control are gels stained with 
coomassie blue. Graphs in the inferior panel are HDAC 
activity expressed as ODs, in the same scale as the positive 
and negative controls that are also HeLa cells extracts with 
and without trichostatin A treatment. At the bottom are val-
ues of valproic acid in serum.
Western blots for anti-acetylated H3 and H4 histones pre-  and post-treatment in PBMN cells of patients 1, 2, 5, and 8 Figure 4
Western blots for anti-acetylated H3 and H4 histones pre- 
and post-treatment in PBMN cells of patients 1, 2, 5, and 8. 
Patient 1 and 2 received a dose of 20 mg/kg, whereas patients 
5 and 8 each received a dose of 30 mg/kg. Positive and nega-
tive controls are HeLa cells treated or not with thrichostatin 
A. Loading control are gels stained with Coomassie blue.Molecular Cancer 2005, 4:22 http://www.molecular-cancer.com/content/4/1/22
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tetrapeptides, benzamides, and short-chain fatty acids
[22].
The discovery that valproic acid-which belongs to the
short-chain fatty acids category and resulted to be an effec-
tive HDAC inhibitor [17,18]-encouraged investigation of
this agent as a potential cancer therapy agent. Valproic
acid can be administered as such or as sodium or magne-
sium salts, but all three forms have the same pharmacok-
inetic behaviour and anticonvulsant effect [23]. Here we
demonstrate that magnesium valproate, when used at
only slightly higher doses than those used as anticonvul-
sant, not only produces H3 and H4 histone
hyperacetylation in PBMN cells but also leads to hyper-
acetylation of H3 and H4 and inhibition of HDAC activity
in tumors.
Preclinical data has shown that valproic acid inhibits the
majority of class I and II HDAC at CI50, varying from 0.7–
1.3 mM [24]; however, the concentration needed in vitro
to achieve its biological effects varies from system to sys-
tem, but in some cases the concentration required is lower
than 0.5 mM in tumors such as glioma, hematopoietic, or
breast cancer cell lines [24-26]. On the other hand, it is
also known that the inhibitory effect of valproic acid on
HDAC begins and disappears within hours after exposure,
with a rapid return of baseline acetylation on histones
[24]. This knowledge suggests that valproic acid, for effec-
tive use in the clinical setting, should be administered
continuously and perhaps for long periods. Nonetheless,
despite the fact that the therapeutic window of valproic
acid is very wide (50–100 µg/mL), there is a clear dose-
effect relationship with depressed level of consciousness
[27] therefore we felt important to investigate if doses
below 60 mg/Kg which produce grade III toxicity lead to
histone hyperacetylation in tumors.
These facts led to us to perform this phase I study to find
the "adequate" biological dose of magnesium valproate.
The advent of the so called "targeted therapies" has led to
reconsider the appropriateness of the traditional or classi-
cal designs for phase I trials which takes into account tox-
icity as the most important parameter for dose escalation.
Instead some authors have proposed that the endpoint in
phase I studies of targeted therapies should be a change in
the level or activity of the target or enzyme or other surro-
gate marker [28]. Because it is clear that the antiprolifera-
tive, differentiating and/or pro-apoptotic effects of HDAC
inhibitors result from the histone hyperacetylation it
seems logical to evaluate the acetylation status of H3 and
H4 histones as the endpoint of the trial. On the other
hand, not necessarily, the highest hyperacetylation should
occur at the higher dose of the tested agent, being possible
that a plateau in the effect can be seen in a range of doses
that do not produce limiting toxicity. In this sense, the
concept of "adequate" instead of the "optimal" biological
dose emerges because, by one hand, the number of
patients required for finding the optimal dose may be to
high for an agent that by itself (or as a single agent) is
expected to produce a negligible clinical response rate or
tumor shrinkage which equate to expose a larger number
of patients to a potentially ineffective agent by its own
[29,30]. Another issue for selecting adequate instead of
optimal dose design is the fact that it allows investigators
to quickly proceed to phase II trials (usually along with
chemotherapy or radiation). Perhaps the only situation
where an optimal dose design is preferred accounts when
the study drug is planned to proceed to larger phase III tri-
als [31].
On this basis, we opted to perform an "adequate" dose
phase I. To our surprise, using doses as low as 20–40 mg/
kg, the biological effect was observed, being remarkable
that no patient presented any grade 3 event. In nine
patients, depressed level of consciousness was grade 2.
Molecular efficacy in terms of H3 and H4 hyperacetyla-
tion in tumors was observed in most patients; in fact if we
take into account the effects on H3, at 20 mg/Kg 2 out of
2 evaluated (100%) had hyperacetylation, 3 out of 4 at 30
mg/Kg (75%), and 4 out of 4 (100%) patients at 40 mg/
Kg. For H4 a very similar pattern emerged 2/2 (100%), 3/
4 (75%) and 2/4 (50%) had hyperacetylation at 20 mg, 30
mg and 40 mg/Kg. When evaluating for both H3 and H4
acetylation the numbers are 2/2 (100%), 2/4 (50%), and
2/4 (50%). Overall, despite the limited number of
patients, inherent to the study design it is clear that at the
range of doses tested there is a plateau in the molecular
response (100%, 50% and 50%) for the three tested
doses. In cases like this when there is a tie in efficacy, the
highest dose should be selected, and hence we have
selected the dose of 40 mg/Kg for our phase II studies [29].
Currently, there is no information concerning the effect of
HDAC inhibitors upon acetylation of H3 and H4 in solid
tumors of patients. Two reports on depsipeptide have
demonstrated hyperacetylation of PBMN cells in two
patients with cutaneous T-cell lymphoma and two
patients with refractory neoplasms as evaluated by
immunoflouorescent labelling [32,33]; additionally, in a
clinical study of SAHA for lymphoma and solid tumors it
was reported that three of five patients showed increased
accumulation of acetylated H3 in the post-treatment
biopsy sample [34]. These data are in agreement with our
findings indicating that the hyperacetylating effect is clin-
ically achievable with these HDAC inhibitors.
The inhibitory activity of HDAC in cells shown by this
class of compounds always parallels changes in H3 and
H4 acetylation [24]. We demonstrate herein that valproic
acid produces a decrease in HDAC activity in tumorsMolecular Cancer 2005, 4:22 http://www.molecular-cancer.com/content/4/1/22
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which is accompanied by histone hyperacetylation sug-
gesting that the H3 and H4 hyperacetylation occurring in
tumors is a consequence of HDAC inhibition. On the
other hand, it is remarkable that three out of the four cases
assayed by H3 and H4 acetylation by western blot in
PBMN cells (patients 1, 5 and 8) their corresponding
tumors had hyperacetylation showing the concordance
between the findings in tumors and PBMN cells. These
data suggest that HDAC activity in the tumor or H3 and
H4 acetylation status in the PBMN cells can be good sur-
rogate markers for monitoring the effect of HDAC inhibi-
tors in clinical trials.
The pharmacokinetics of valproic acid has extensively
been studied. Because its half-life is between 8–16 hours,
the steady-state concentrations can be determined as soon
as at day 4 of treatment [35,36]. Under this rational we
determined the levels of valproic acid at day six, within 8–
10 hours of the last dose taken, hence the sera values
obtained are representative of the levels at the steady-
state. High interindividual variation in the pharmacoki-
netics of valproic acid in epileptic patients is well-known
[37]. This phenomenon was observed in our study with
serum concentrations ranging from 73.61 to 170.49 µg/
mL, and in addition there was no correlation with dose
level and mean concentration achieved; thus, for doses of
20, 30, and 40 mg/kg, mean concentrations were 94.06,
123.46, and 90.93 µg/mL, respectively. This finding, how-
ever, could be derived from the small number of patients
we analyzed, because Tisdale et al. demonstrated signifi-
cant linear correlation between VPA dose and serum con-
centration in a sample of 60 epileptic patients [37].
Alternatively, it can be suggested that like in cell lines,
which show high variability in response to HDAC inhibi-
tors [24-26], interpatient variability in tumors may exist.
There is one report in abstract form proceeding from a
clinical study with valproic acid. Atmaca et al., performed
a "traditional" dose escalating phase I study using valproic
acid by intravenous infusion in patients with advanced
cancer. In the study, 26 patients pre-treated and with pro-
gressive malignant disease received the drug by 1-h infu-
sion split twice a day for 5 consecutive days, repeating the
treatment at intervals of 2 weeks in cohorts of 60, 75, 90,
and 120 mg/kg dosages. These investigators found maxi-
mum tolerated dose of 60 mg/kg because 9 of 26 patients
presented grade 3/4 neurological toxicity. In addition,
these authors reported hyperacetylation of PBMN cells in
the majority of patients; nevertheless, they provided no
information on serum levels achieved or the molecular
response according to the dose level [38].
In a phase I-II study of the combination of decitabine and
valproic acid for myeloblastic acute leukemia and myelo-
dysplastic syndrome, a fixed dose of 15 mg/m2 of decitab-
ine and valproic acid at 20, 35 and 50 mg/Kg were
administered every 10 days. The toxicity observed was
grade III neurotoxicity at 50 mg/Kg in 1 of 10 and grade II
in 5 out 10 patients. Subsequently, VPA 50 mg/kg was
chosen for the phase II portion of the study. Of 40 evalu-
able for response, an overall response rate of 22% (8 PR
and 1 CR) was observed. Interestingly, the response rates
according to the valproic acid dose were 33% for 20 mg,
11% for the 35 mg and 25% for the 50 mg/Kg dose level
[39]. Finally, in a third phase I study for metastatic solid
tumors valproic acid was administered as an IV loading
dose followed by 5 doses of oral doses given every 12
hours followed by a dose of epirubicin at day 3. At the
time of reporting, 16 patients have been treated at 4 dose
levels: VPA 15, 30, 45, and 60 mg/kg; with epirubicin at
75 mg/m2. The maximum tolerated dose has not been
reached and dose escalation is continuing. Major
responses were observed in all tumor types including in
anthracycline failures and in anthracycline-resistant
cancers such as melanoma and cervical carcinoma.
Plasma levels were not reported, however, there were
above the concentrations needed for in-vitro synergy [40].
The extensive use of valproate as anticonvulsant has
shown excellent tolerability in the therapeutic range
between 50 and 100 µg/mL [15,16]. Despite the fact that
levels >100 µg/mL are considered supra-therapeutic [41],
it must be stressed that in the our present study four
patients presented concentrations higher than that level
(109.12, 146.56, 170.49, and 107.43 µg/mL), and that
none of these patients presented any grade 3 toxicity,
which indicates the feasibility of achieving these levels
during treatment to maximize the chances of producing
tumor hyperacetylation. In fact, significant clinical
adverse effects of valproic acid ingestion, such as lethargy,
coma, tachycardia, metabolic acidosis, and hypotension,
are more likely to occur with concentrations >450 µg/mL
[41].
All together, existing data suggest that molecular and clin-
ical responses occur at valproic acid doses between 20 and
60 mg/Kg. The optimal biological dose of valproic acid
remains to be determined, however, our results suggest
the existence of a plateau in the histone acetylation at
doses between 20 and 40 mg/Kg. Based on that we have
chosen 40 mg/Kg as the dose to test in phase II trials.
Synergy of HDAC inhibitors with demethylating agents
for reactivating expression of tumor suppressor genes as
well as to induce antitumor effects is well-known [42-44].
In this regard, our group showed that hydralazine is an
effective demethylating agent that reactivates the tumor
suppressor genes expression silenced by methylation
[45,46] and reported the results of a phase I study demon-
strating the gene demethylating and reactivating activityMolecular Cancer 2005, 4:22 http://www.molecular-cancer.com/content/4/1/22
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of the drug at doses between 75 and 150 mg/day [47]. On
these bases, we at present are testing these two drugs-
demethylating hydralazine and the HDAC inhibitor valp-
roic acid-plus chemotherapy or plus chemoradiation in
phase II studies for solid tumors.
Conclusion
Our results provide evidence that magnesium valproate at
doses between 20 mg and 40 mg/Kg, inhibits deacetylase
activity and hyperacetylates histones in tumor tissues. Its
clinical efficacy along with a demethylating agent plus
chemotherapy or radiation is currently being tested in
phase II studies.
Methods
Patient selection
Previously untreated patients with histological diagnosis
of carcinoma of the cervix uteri entered into this phase I
study. Patients were invited to participate in the study in
the waiting time from diagnostic evaluation to commenc-
ing chemoradiation. The whole study period lasted only 6
days, hence valproic acid treatment was not repeated.
The following inclusion criteria were applied: 1) age
between 18 and 75 years; 2) World Health Organization
Performance Status 0–2; 3) hematological, renal, and
hepatic functions as follows: hematological: hemoglobin
≥10 g/L; leukocytes >4,000/mm3, platelets >100,000/
mm3, total bilirubin and transaminasas <1.5× the normal
upper limit, and normal serum creatinine; 4) normal
chest x-ray, and 5) signed informed consent for study
medication and biopsies pre and post-treatment. Exclu-
sion criteria included the following: 1) history of allergy
to valproic acid; 2) any past or current central nervous sys-
tem pathologic condition (epilepsy, etc.) that required
pharmacologic treatment; 3) any current hepatic disease;
4) uncontrolled infection or other systemic diseases; 5)
concomitant treatment with any experimental drug; 6)
pregnant or nursing women; 7) mental illness, and 8) pre-
vious or concomitant malignant diseases other than non-
melanoma skin cancer. The Institutional Regulatory
Board approved the study protocol.
Clinical samples
Biopsies were taken from areas with visible macroscopic
cervical tumor using a sterile biopsy punch the day before
and the day six after the five days of magnesium valproate
treatment. (The post-treatment biopsy and peripheral
blood sampling were taken in the early morning, between
8 and 10 hours after the last dose of magnesium val-
proate). Part of the biopsy was sent to the Institution's
Pathology Department for routine Hematoxilin & eosin
diagnosis. The remaining biopsy specimen was immedi-
ately frozen at -20°C for biological analyses. In addition,
a blood sample of 10 mL was drawn from the arm by
venipuncture to obtain serum and the mononuclear cell
fraction for protein extraction.
Magnesium valproate treatment
After tumor and blood sampling, patients were divided
into the following groups and started oral magnesium val-
proate for a five-day period: I) 20 mg/kg, II) 30 mg/kg; III)
40 mg/Kg. Total dose was divided in three administra-
tions every 8 h (8 AM, 4 PM and 12 PM) per oral route in
enteric-coated tablets of 200 and/or 400 mg. Biological
effects of treatment on tumor and peripheral blood sam-
ples as well as clinical and laboratory toxicity were
assessed at the end of the study period (6 days). Patients
then went to receive the definitive chemoradiation treat-
ment as planned.
Toxicity was registered according to the Common Toxicity
Criteria of the National Cancer Institute (CTC NCI) with
special emphasis on the presence, throughout the
treatment days, of known signs and symptoms associated
with magnesium valproate treatment such as somno-
lence/sedation and fatigue. Therapeutic levels of valproic
acid were also evaluated in blood serum at day 6, between
8 and 10 hours after the last dose of magnesium valproate.
Acid extraction of proteins
Acid extraction of histones was performed as described
previously [48] with modifications. Briefly, tumor sam-
ples and mononuclear cell pellets were suspended in 10
volumes of PBS and centrifuged at 200 × g for 10 min.
Cells were then suspended with five volumes of lysis
buffer [10 mM HEPES (pH 7.9), 1.5 mM MgCl2, 10 mM
KCl, 0.5 mM DTT, and 1.5 mM phenylmethylsulfonyl
fluoride] and hydrochloride acid at a final concentration
of 0.2 M and subsequently lysed on ice for 30 min. After
centrifugation at 11,000 × g for 10 min at 4°C, the cell
supernatant fraction that contained acid-soluble proteins
was retained. Supernatant was dialyzed against 200 mL of
0.1 M acetic acid twice for 1–2 h each and then dialyzed
against 200 mL of H2O for 1 h, 3 h, and overnight. Dialy-
sis was performed using a Spectra/Pore 3 Dialysis Mem-
branes 3,500 MWCO (Spectrum Laboratories, Inc.,
Rancho Dominguez, CA, USA).
Western blot analysis
Acid extracted proteins were analyzed by sodium duo-
decyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE)/immunoblotting with antibodies recognizing
acetylated histones (rabbit polyclonal IgG, anti-acetyl-his-
tone H4, and rabbit polyclonal-anti-acetyl-histone H3;
Upstate Biotechnology, Lake Placid, NY, USA). Protein
samples were separated along with molecular weight
markers (Bio-Rad, Hercules, CA, USA) in 15% polyacryla-
mide gels. Gels were transferred onto 0.45-µm nitrocellu-
lose membranes (Schleicher and Schuell, Keene, NH,Molecular Cancer 2005, 4:22 http://www.molecular-cancer.com/content/4/1/22
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USA). Gel loading equivalence was confirmed by
Coomassie blue stain (Sigma, St Louis, MO, USA). Spe-
cies-specific immunoglobulin G-horseradish peroxidase
(IgG-HRP) secondary antibodies were purchased from
Bio-Rad. Blots were developed with chemiluminescent
substrate (Amersham International, Buckinghamshire
England), and autoradiography was performed utilizing
X-OMAT film (Kodak, Rochester, NY, USA).
Histone deacetylase assay
Assays were performed using the colorimetric HDAC
activity assay from BioVision (BioVision Research Prod-
ucts, Mountain View, CA, USA) according to manufac-
turer instructions. Briefly, 50 µg of nuclear extracts from
tumors were diluted in 85 µL of ddH2O; then, 10 µL of
10× HDAC assay buffer were added followed by addition
of 5 µL of the colorimetric substrate; samples were incu-
bated at 37° for 1 h. Subsequently, the reaction was
stopped by adding 10 µL of lysine developer and left for
additional 30 min at 37°C. Samples were then read in an
ELISA plate reader at 400 nm. HDAC activity was
expressed as relative OD values per µg of protein sample.
The kit contains negative and positive controls that con-
sist of nuclear extract of HeLa treated or not with trichos-
tatinA, respectively.
Blood levels of valproic acid. Valproic acid was measured
in serum using a fluorescence polarization immunoassay
(FPIA) technology. This is a competitive binding immu-
noassay technology in which fluorescein-labeled and
patient antigens compete for binding sites on antibody
molecules [49]. Polarization of the fluorescent light emit-
ted from labeled drug-antibody complex is inversely
related with amount of drug in the sample. TDx/TDxFLx
analyzer and the valproic acid kit REF9514 were obtained
from Abbott Laboratories (Abbott Laboratories, Abbott
Park, IL, USA). Blood samples were obtained in an sst-gel-
clot activator tube 8 h after the last dose of magnesium
valproate and assays were conducted following manufac-
turer instructions; 100-µL samples of serum were run by
duplicate and values expressed as µg/mL.
Statistical analysis
All numerical data were expressed as average of values
obtained ± standard deviation (SD). Statistical signifi-
cance was determined by conducting a paired Student t
test.
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